M.A.P.: member of the RED‐HF Clinical Endpoint Committee and Executive Committee (no payments in the last 12 months); grants from Novartis and Sanofi; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, DalCor, Gilead, GalaxoSmithKline, Janssen, Lilly USA, The Medicines Company, Merck, Novartis, Novo Nordisk, Relypsa, Sanofi, Thrasos, Genzyme and Teva; The Brigham and Women's Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis. This evidence concerns the gene REN and hydrops fetalis.